262 related articles for article (PubMed ID: 37404815)
1. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
3. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
[TBL] [Abstract][Full Text] [Related]
4. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV.
Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C
Front Immunol; 2023; 14():1264160. PubMed ID: 38045691
[TBL] [Abstract][Full Text] [Related]
5. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
[TBL] [Abstract][Full Text] [Related]
6. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
[TBL] [Abstract][Full Text] [Related]
7. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
8. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.
Zou S; Guo W; Wu S; Ming F; Tan Y; Wu M; Tang W; Liang K
Front Immunol; 2022; 13():988304. PubMed ID: 36325346
[TBL] [Abstract][Full Text] [Related]
9. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
[TBL] [Abstract][Full Text] [Related]
10. Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
Zhan H; Gao H; Liu Y; Zhang X; Li H; Li X; Wang L; Li C; Li B; Wang Y; Dai E; Li Y
J Med Virol; 2023 Jan; 95(1):e28428. PubMed ID: 36571267
[TBL] [Abstract][Full Text] [Related]
11. The humoral and cellular immune responses following booster vaccination with SARS-CoV-2 mRNA in people living with human immunodeficiency virus.
Matsumoto Y; Murata M; Ohta A; Yamasaki S; Ikezaki H; Toyoda K; Shimono N
J Infect Chemother; 2024 May; 30(5):417-422. PubMed ID: 37977325
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Vanetti C; Stracuzzi M; Crivellaro E; Ciciliano F; Garziano M; Fenizia C; Biasin M; Rubinacci V; Amendola A; Tanzi E; Zuccotti GV; Clerici M; Giacomet V; Trabattoni D
Front Immunol; 2023; 14():1301766. PubMed ID: 38250079
[TBL] [Abstract][Full Text] [Related]
13. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
16. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.
Zou S; Wu M; Ming F; Wu S; Guo W; Marley G; Xing Z; Zhang Z; Zeng M; Sun C; Zhang J; Tang W; Liang K
AIDS Res Ther; 2022 Jul; 19(1):33. PubMed ID: 35791004
[TBL] [Abstract][Full Text] [Related]
17. Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
Res Sq; 2022 Jun; ():. PubMed ID: 35794897
[No Abstract] [Full Text] [Related]
18. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A; Matusali G; Lepri AC; Cimini E; Fusto M; Colavita F; Gagliardini R; Notari S; Mazzotta V; Mariotti D; Cicalini S; Girardi E; Vaia F; Maggi F; Antinori A;
Int J Infect Dis; 2023 Sep; 134():195-199. PubMed ID: 37343783
[TBL] [Abstract][Full Text] [Related]
19. Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
Jin J; Wang X; Li Y; Yang X; Wang H; Han X; Sun J; Ma Z; Duan J; Zhang G; Huang T; Zhang T; Wu H; Zhang X; Su B
Chin Med J (Engl); 2023 Dec; 136(24):2938-2947. PubMed ID: 37963586
[TBL] [Abstract][Full Text] [Related]
20. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
